Exemestane marks a major change in the way doctors treat hormone-dependent cancers, especially breast cancer in postmenopausal women. As a drug, its roots track back to the evolving battle against cancer since the 1990s, stepping up when tamoxifen and non-steroidal aromatase inhibitors reached their limits. Like many breakthroughs, its arrival reflects years of cooperation—lab scientists, clinicians, companies, patients willing to join early trials. Across Europe and North America, the race to design molecules that block estrogen production saw chemists playing with multiple scaffolds. Exemestane stood out for showing persistent estrogen suppression where others failed, earning its spot first in clinical breast cancer protocols, then FDA approval, and eventually global adoption. It reshaped choices for those living with persistent or metastatic disease, often extending lives or delaying recurrence when other options started losing ground.
Exemestane, marketed under names like Aromasin, belongs to the steroidal aromatase inhibitor family. Unlike non-steroidal types such as anastrozole, it irreversibly binds to aromatase, taking on its enzyme adduction permanently. Structurally, it mimics the natural substrate—androstenedione—with a key tweak at the 6-methylene, fooling the body’s estrogen-producing machinery. Formulations vary, but most on the market come as oral tablets, usually designed for once-daily dosing at 25 mg strength. Companies focus on stable, easily absorbed forms to help patients handle the daily burden of long-term therapy. In real world use, side effects like joint pain, fatigue, or bone thinning frame the clinical conversation, but for many, the benefit in survival far outweighs the risk.
In pure form, exemestane appears as a white or off-white crystalline powder, faintly bitter on the tongue. Its empirical formula, C20H24O2, sets up a molecule packed with twenty carbon atoms, echoing its steroid backbone. The melting point hovers around 155-160°C, which says much about its stability under normal handling. Solubility tells another story—exemestane dissolves well in ethanol, methanol, and chloroform, but resists water, so formulating for oral delivery needs careful design. The log P value, describing its lipid solubility, cuts to the core of how it passes through cell membranes, crucial for blocking estrogen synthesis inside tissues. Understanding these properties shapes not just manufacturing, but dosing, storage, and even package instructions, reflecting years of fine-tuning and feedback from pharmacists and chemists alike.
Looking across global regulatory filings, strengths often come down to 25 mg per tablet, given once daily with food to maximize absorption and minimize stomach upset. Labels spell out storage needs—ideally below 25°C, dry and dark—because moisture and heat threaten the powder’s integrity. Whether generic or brand name, excipients include lactose, magnesium stearate, and microcrystalline cellulose, ingredients picked for their safety profile and compatibility with the main molecule. Manufacturers post warnings for women of childbearing potential, flagging its use for postmenopausal adults only. Labels must include batch number, expiry, lot traceability, and a clear breakdown of inactive ingredients, which came about precisely because early users flagged allergies and cross-reactions. These details matter as much for the safety-conscious patient as for clinics trying to comply with evolving pharmaceutical rules.
Exemestane’s manufacture draws on synthetic organic chemistry, starting from androstane skeletons found in nature or built up in a lab. The critical step pivots on introducing that signature 6-methylene group, usually via a Wittig reaction or modified olefination. At each stage, purification becomes a tug-of-war between yield and removing potentially harmful byproducts. The API (active pharmaceutical ingredient) gets characterized by nuclear magnetic resonance, IR, and HPLC to ensure purity above 99%—a bar set after years of mishaps with less stringent controls. Only after batch testing for quality, and careful granulation, do companies press the API into compressed tablets. For large-scale batches, maintaining consistent quality tests patience and precision from chemists and engineers alike, since any slip prompts costly recalls and impacts vulnerable patients. This painstaking attention to process, learned from past errors, builds trust for both prescribers and patients staring down a tough diagnosis.
The chemistry behind exemestane goes deeper than basic synthesis. Scientists have introduced analogues with tweaks at C-6 or at the D-ring, often hoping for better activity or reduced side effects. Some labs experiment with conjugating the molecule for longer half-life or to alter tissue selectivity, using esterification or other linkages. The irreversible binding property, central to its action, comes from forming a covalent adduct with the aromatase enzyme—a rare trick that sets steroidal inhibitors apart. Degradation studies show it resists breakdown under acidic and neutral conditions, but alkaline hydrolysis cracks it open, generating familiar steroid-like fragments that analysts track to confirm product authenticity. While most modifications seek to sharpen its anticancer edge, a few target making it more friendly for skin-based or depot delivery, anticipating future needs as patient populations change.
Across continents, exemestane shows up under names like Aromasin, Aromaset, Exemestan, and X-Tane, reflecting branding habits in different regions. Each name ties to the same INN—Exemestane—but formulating countries print trade names to lock down market share or escape lingering patents. Synonyms in chemical literature include 6-methyleneandrosta-1,4-diene-3,17-dione, as well as its registry numbers in the CAS (107868-30-4) or through the USAN. Pharmacy shelves sometimes swap in generics soon after exclusivity lapses, but ingredient lists and certificates of analysis guarantee interchangeability. For researchers, keeping track of all synonyms during literature reviews or purchasing avoids the headache of ordering the wrong compound—or missing key data in systematic reviews. Knowing the list of names, like much in pharmacology, means fewer errors for both seasoned chemists and early-career scientists.
Handling exemestane safely in the lab or pharmacy is more than protocol—it’s about real risks. Workplace rules require gloves and dust masks during weighing or compounding, since skin or eye exposure may trigger irritation. Storage facilities need controlled temperature, airtight containers, and logs to monitor expiry, since potent drugs degrade unpredictably under poor conditions. In health care, staff check patient records for allergies to excipients and contraindications like pregnancy. Regular audits and clear documentation meet strict standards set by agencies—EMA, FDA, CFDA—after past tragedies with subpar drugs. Waste must go into special containers destined for pharma incineration, so compounds don’t contaminate municipal water. Firms train staff on spill handling—even small errors can mean steep fines or deterred approvals. Everyone working in pharma, from janitor to senior scientist, learns that safety isn’t an afterthought; it shapes every step, out of respect for the patients relying on timely and untainted medication.
Doctors prescribe exemestane to patients with estrogen-receptor positive breast cancer that persists or returns after tamoxifen therapy. In adjuvant settings, it becomes a lifeline against recurrence, since it crushes leftover tumor cells relying on estrogen. Some protocols use it sequentially with other hormone blockers, chasing every angle to cut relapse risk. Research teams have extended trials into higher-risk populations, such as those with BRCA mutations or after risk-reducing surgery. Beyond breast cancer, a few studies explore off-label uses in ovarian or endometrial cancers, but those results remain patchy compared to its proven benefits with breast lesions. Given the side effect of bone demineralization, endocrinologists sometimes coordinate with oncologists to monitor and treat osteoporosis, aiming for overall health instead of just tumor control. Wider interest exists in its subtle action on steroid hormone balance, drawing in researchers from fields like endocrinology, preventive medicine, and even aging.
The push to develop better aromatase inhibitors like exemestane doesn't stop at approvals. In academic and industry labs, researchers probe how tumor subtypes synthesize hormones, why some patients develop resistance, and what molecular changes shift patient response curves. Clinical trials test alternate dosing, combinations with immunotherapies or targeted drugs, and sequencing with other endocrine agents—moving past one-size-fits-all regimens. Biomarker studies map which genes, proteins, or epigenetic marks predict ongoing sensitivity to exemestane, hoping to weed out non-responders early. Drug development teams search for new derivatives or analogues that might dodge the pitfalls of musculoskeletal pain or bone thinning. Some groups experiment with nanoformulations or slow-release implants, driven by patients struggling with the monotony of daily pills. The rise of real-world evidence datasets, including patient-reported outcomes, has shaped new trial guidelines and revealed demographic gaps in older data—pushing for more diverse and personalized approaches.
Toxicity testing started before the first human trials, with animal studies documenting the safe dose range and chronic effects across rodent and primate models. Reproductive toxicity studies found embryo-fetal death in pregnant rats—fueling critical labeling updates that restrict use to non-fertile women. Long-term dosing in mice and dogs tracked organ health, liver enzymes, and potential for secondary cancers—no alarming trends appeared, supporting further development. Clinical trials followed up with side effect tracking—hot flashes, arthralgia, rare hepatic shifts—leading to regular patient bloodwork and bone scans. Post-marketing surveillance teams scan health records for allergic reactions, cardiac patterns, or unusual deaths, mindful that once-rare events can emerge with millions of exposed users. Toxicologists still run studies simulating accidental exposure in children or workers, driving safety data sheets and spill management plans. The push to understand not just efficacy but long-term consequences grows stronger as aging survivors reach decades of exposure.
Exemestane faces a future as both a standard bearer and a springboard for next-generation treatments. The challenge of resistance—tumors rewiring around blocked aromatase—means discovery scientists dig into parallel pathways, seeking new targets. Immunology and precision medicine open the door for combination regimens, where exemestane blocks hormone signals as checkpoint blockers or PARP inhibitors sweep up resistant cells. Digital health unlocks remote adherence monitoring and electronic symptom diaries, letting clinicians spot issues early and support frail or rural patients more closely. Cost reductions from generics extend access to low- and middle-income settings where late-stage cancer dominates. Meanwhile, health economists and social scientists study quality-of-life tradeoffs—balancing risk of recurrence against fatigue, joint pain, and financial burden. The lesson from decades with exemestane is that progress rarely stops; it morphs as patient needs, science, and society shift, keeping one step ahead in the fight against cancer.
People hear about cancer drugs and think of chemotherapy or radiation, but Exemestane tells a different story. This medicine, known by many as Aromasin, is a pill designed to cut off estrogen production in the body. Since certain types of breast cancer rely on estrogen to grow, shutting down that hormone can slow the disease in its tracks. Exemestane stands out for treating postmenopausal women with hormone receptor-positive breast cancer.
My own aunt faced a breast cancer diagnosis, and the doctors explained her tumor listened to estrogen like a radio to a favorite song. After her surgery and rounds of radiation, they put her on Exemestane. She took one tablet a day. It felt simple, but that small pill made a huge difference. Clinical data backs this up: according to the National Cancer Institute, Exemestane can reduce the risk of cancer coming back by cutting off the hormone supply. In studies, women taking Exemestane for two to five years saw lower rates of recurrence compared to those taking a placebo.
The drug finds its main home in women whose bodies no longer produce much estrogen from the ovaries, but instead from other tissues by converting androgens. That conversion happens because of an enzyme called aromatase. Exemestane targets aromatase and blocks it. By lowering estrogen levels further, Exemestane chips away at the fuel source for certain breast cancers.
Every medicine brings its own baggage. Exemestane is no different. My aunt felt hot flashes and stiff joints not long after starting the medication. Aches in her bones and some fatigue reminded me of the stories I’ve read from thousands of other women. The FDA lists bone thinning and increased cholesterol as possible risks. It’s important for women to get bone density scans and take steps to support their bones — exercise, vitamin D, and calcium help. I’ve seen firsthand how a simple daily walk or weight-bearing exercises make a noticeable change in energy and bone strength.
No one should walk this journey alone. Honest talks with doctors matter, especially before starting Exemestane. Women thinking about their next steps need to bring up other health problems, ask about bone health, and talk about managing symptoms. In my aunt’s case, her doctor adjusted her other medications and steered her to a support group. These small acts made each day easier.
The big problem remains access. Some insurance plans bog patients down with paperwork and co-payments, leaving many women wondering if they can afford their pills. Advocacy groups like the Breast Cancer Research Foundation and local charities sometimes step in, but the healthcare system leaves gaps. Building awareness and making coverage simpler for life-saving drugs will make a long-term difference for families like mine.
Exemestane gives many women time – and time, after cancer, means everything. Staying informed and working together, patients and doctors keep pushing the limits of what’s possible after a diagnosis.
Exemestane steps in as an aromatase inhibitor, used mainly for hormone-receptor-positive breast cancer in postmenopausal women. It works by cutting down estrogen in the body, making it harder for certain tumors to grow. That’s a powerful thing, but this medicine isn’t soft on the body. Having walked with family through similar cancer treatments, I’ve seen every side of the journey—relief, worry, pain. I’ve listened to nights where hot flashes didn’t let anyone sleep and mornings when joints refused to move easily.
Some side effects pop up early on and can stick around. Hot flashes show up for most people, heating up the night and leaving bedsheets drenched. Joint pain creeps in, making knees stiff and fingers slow. The aches can feel like you aged ten years overnight. Fatigue sits heavy, turning simple errands into mountains. People tell stories of making coffee, then needing to rest a whole hour. Sweating more than usual sneaks up too, and the smell throws off confidence.
Bone pain makes people worry. Exemestane's drop in estrogen can thin out bones faster, setting the stage for osteoporosis. One friend’s mother broke her wrist just stepping off a curb. Doctors sometimes check bone density often, looking for early warning signs.
Mood swings or depression shouldn’t catch anyone by surprise. Watching a loved one cry over small things—bills, commercials, a stubborn zipper—shows how delicate everything can feel. Anxiety can rise, creating fear over cancer coming back or just from not feeling like yourself. Some women say the mental side effects made them want to quit treatment more than any physical pain.
Nausea and appetite changes chase away comfort food. People sometimes lose weight, not out of choice but because nothing tastes right. Insomnia takes rest away, and headaches make thinking even harder. Some experience hair thinning—not the full hair loss of chemo, but enough to worry. Sweating and dizziness leave folks afraid to drive or walk alone.
More rarely, women notice swelling in hands or feet. Liver enzymes may rise, picked up on blood work. If chest pain or trouble breathing shows up, that calls for a doctor’s attention right away. These might signal allergic reactions or heart strain, and delaying care puts lives at risk.
No need to suffer alone. Oncologists expect these bumps in the road and can suggest changes before things get out of control. Over-the-counter pain medicine, staying active, and getting enough calcium and vitamin D all help with bone and joint problems. Asking family for help, setting small goals, and reaching out to peer groups ease the mental pressure. Sharing how you feel with loved ones means people can watch for changes you might not spot yourself.
If one side effect stands out—bone problems, mood changes, severe hot flashes—a quick call to the cancer clinic can open up other options. Medicines exist for nearly every symptom, and switching treatments sometimes makes sense. Lab tests or bone scans keep everyone on the same page. Exemestane does heavy lifting for cancer, but patients shouldn’t carry the weight alone. With teamwork from care providers and support from family, side effects become just another part of the story, not the end of it.
Doctors usually bring up exemestane for people with hormone-sensitive breast cancer, especially when other treatments haven’t finished the job. The science behind it: this medicine blocks aromatase, a little enzyme your body uses to make estrogen. Lower estrogen helps stop hormone-driven tumors from growing or coming back after you’ve already tackled surgery or chemotherapy.
From my experience with friends and family who’ve gone through cancer treatment, prescription instructions can feel almost sacred. Doctors have reasons for the smallest details—a certain dose, a set time of day. The classic routine for exemestane: once a day, after a meal. Taking it after food doesn’t just protect your stomach; it actually helps your body absorb more medicine. Skipping breakfast and popping the pill can leave you with less protection than you might think.
A daily medicine gets built into your routine, just like brushing your teeth. Missed days happen to everyone, but catching up means taking the missed dose as soon as you remember—unless it’s already time for the next one. Doubling up isn’t safe. Exemestane packs a punch, and too much can trigger stronger side effects like joint pain, fatigue, or hot flashes.
People sometimes feel tempted to adjust their dose if side effects show up. My own family members have had moments like this, out of frustration or fear, thinking maybe smaller doses or skipping a day could help. Physicians know how to balance symptom relief with cancer defense. If the treatment wears you down, let your care team know. Honest conversations help them pick solutions that support both your quality of life and the goals of your therapy—sometimes switching the time you take it, or adding other medicines to tackle side effects.
Exemestane might clash with supplements or other pills. Doctors and pharmacists ask about everything you take because certain vitamins or over-the-counter meds could cut down exemestane’s strength or increase risks. Grapefruit, for instance, can mess with the levels of lots of medicines—exemestane included. Doctors don’t say these things just to sound smart. If you hear a warning, there’s a real reason.
Living with cancer means embracing regular check-ins, blood tests, and symptom reports. Let your doctor know if your body feels different, even in small ways: bone aches, mood swings, thinning hair. These might sound minor, but over time, unchecked bone loss or liver issues can lead to bigger problems. Regular monitoring gives your care team a chance to spot trouble before it grows.
Going through breast cancer treatment doesn’t just affect your body. Mental and emotional strain comes with the territory. Peer groups and counseling help many people manage the burden of long-term medication. Hearing from other patients keeps you grounded and sometimes offers strategies for the tough days—like tips for managing hot flashes, dietary swaps for bone strength, or even just reminders that you’re not alone in this fight.
Taking exemestane isn’t about following orders blindly. It’s about understanding what the medicine does for your body and being open about what happens along the way. The surest way through a diagnosis is working with your doctor, asking questions, and tracking your own responses. That partnership shapes every part of your journey, giving you the best shot at staying healthy and living well.
Exemestane sits in the toolbox for many women facing hormone-receptor-positive breast cancer. Doctors prescribe it to block estrogen production, which slows cancer growth. It matters, because after a diagnosis, the stack of pill bottles starts to add up. Many women juggling exemestane also reach for drugs that handle pain, blood pressure, or anxiety.
Taking multiple prescriptions is a reality for cancer patients, and ignoring those potential mix-ups leads to real risks. Some drugs push liver enzymes into overdrive or slow them down. Exemestane breaks down in the liver, so adding other prescriptions shifts how fast or slow it leaves the system. For example, rifampin, used for serious infections, speeds up liver enzymes. Taking it with exemestane can empty your body of the cancer drug too quickly—leaving less in your bloodstream and lowering its punch.
Common painkillers, statins for cholesterol, and antidepressants all run through the same system. Not every medicine causes trouble, but certain ones stand out. Some antifungals and seizure drugs force liver enzymes into high gear, reducing exemestane’s effects. Blood thinners bring in a different risk: they can cause unexpected bleeding, which complicates everything. Even over-the-counter remedies like St. John’s Wort, a popular herbal supplement for mood, ramps up these enzymes and chips away at exemestane’s benefits.
Pharmacists and oncologists encourage patients to carry a running list of their medicines, even the “natural” ones. Bringing that list to each appointment helps doctors spot problems. Real-world mistakes crop up when patients forget to mention a new supplement, or feel embarrassed to admit they’re using herbal remedies alongside their prescriptions. I’ve seen friends shrug off these talks, only to land in the ER after a drug interaction sent blood counts in the wrong direction.
After watching a loved one go through breast cancer treatment, I learned that health instructions printed in a pamphlet don’t always match up with real lives. One doctor catches a dangerous interaction, while another might miss it if the information stays hidden. Some people flip between specialists, increasing the odds of missing something important. Many patients trust their prescriptions are safe together, not realizing how fast another medicine can tip the balance. The stories that stick with me aren’t always about the newest drug, but about the side effects nobody warned them were coming.
Keep every doctor informed, even if a medication feels unimportant. If you start a new herbal supplement, report it—they aren’t harmless, especially with hormone-blocking drugs. Use one pharmacy, or make sure all pharmacies know your full list to catch interactions early. If new symptoms show up, like bruising, fatigue, or mood changes, report them. These can hint at a bad reaction brewing between drugs.
Doctors and pharmacists know these risks, but patients carry the most up-to-date information about what’s really getting swallowed each day. Staying honest with your care team protects you. Medicine can do wonders when used with clear information guiding every step.
Exemestane controls the body's estrogen level. Doctors prescribe it mostly to women with certain types of breast cancer, especially after menopause. The drug works by lowering estrogen in the body, slowing the growth of hormone-sensitive tumors. Many people benefit, but it's not a one-size-fits-all treatment. Knowing who should avoid it keeps people safe and can save a lot of trouble down the road.
This medicine does not target tumors driven by hormones in women who have not gone through menopause. Estrogen in pre-menopausal women comes mainly from the ovaries. Lowering estrogen with this drug works better after menopause. I’ve seen young women believe this drug might speed up recovery, only to face side effects and zero benefit. Doctors have guidelines that almost always steer younger women away from this option.
Some people carry allergies that don’t always pop up on medical charts. Anyone with a history of severe reactions to drugs, especially similar compounds, should tell their doctor before starting Exemestane. Rashes, swelling, trouble breathing, and other severe symptoms came up in rare clinical cases, documented by the FDA. Skipping a talk with your healthcare team could set up a dangerous situation.
I remember a young mother-to-be facing breast cancer. The oncologist explained in clear terms that Exemestane can harm an unborn child. Scientists have shown in animal studies that the drug gets through the placenta and causes serious problems for the fetus. Nursing mothers face a similar risk, as the drug can leak through breast milk. For pregnant or breastfeeding women, the best option includes talking clearly with doctors about alternative therapies.
Liver or kidney problems can change how drugs travel and act inside the body. These two organs filter and process almost everything we swallow. If they do not work well, Exemestane can build up to dangerous levels. Research published in leading journals has shown worse side effects in women with existing liver or kidney issues. Doctors usually pick drugs that the body can handle safely in these cases.
This drug takes a toll on bone health. My grandmother, for example, struggled with bone thinning after her breast cancer treatment. She took Exemestane for a short time, but bone scans showed it made things worse. For anyone with weak bones or a history of fractures, the risk can outweigh the benefits. Doctors can run simple bone tests and help pick a safer route, sometimes pairing the drug with bone-strengthening methods for those whose benefits outweigh the risks.
Mixing drugs can lead to bad reactions. Exemestane reacts with hormone replacement therapies and some cancer drugs. Hospitals have safeguards, but communication between patients and doctors is still essential. Every prescription, supplement, or over-the-counter medicine should be shared before starting a new drug. Pharmacists and doctors keep up with ever-changing lists of drug interactions, so double-checking helps avoid dangerous effects.
Not everyone fits the textbook definition of an "ideal" candidate for Exemestane. Honest talks and regular monitoring go a long way. Staying informed and working closely with healthcare providers leads to safer, more effective care.
| Names | |
| Preferred IUPAC name | 6-methylideneandrosta-1,4-diene-3,17-dione |
| Other names |
Aromasin
Aromasinum Exemestan FCE 24304 |
| Pronunciation | /ɛkˈsiː.mɛs.teɪn/ |
| Preferred IUPAC name | (1S,2S,4S,6R,8R,9S,13S,14S)-6-methylidene-2,13-dimethyl-3-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one |
| Other names |
Aromasin
Exemestan Aromasinum FCE 24304 SC-46488 |
| Pronunciation | /ɛkˈsɛm.ɛs.teɪn/ |
| Identifiers | |
| CAS Number | 107868-30-4 |
| Beilstein Reference | 1723886 |
| ChEBI | CHEBI:62002 |
| ChEMBL | CHEMBL966 |
| ChemSpider | 54653 |
| DrugBank | DB00990 |
| ECHA InfoCard | 100.098.457 |
| EC Number | 3.3.2.39 |
| Gmelin Reference | 1366240 |
| KEGG | D04077 |
| MeSH | D000067353 |
| PubChem CID | 60198 |
| RTECS number | XN9438000 |
| UNII | FMO09X4CBZ |
| UN number | UN2811 |
| CAS Number | 107868-30-4 |
| Beilstein Reference | 1694108 |
| ChEBI | CHEBI:116111 |
| ChEMBL | CHEMBL1152 |
| ChemSpider | 54666 |
| DrugBank | DB00990 |
| ECHA InfoCard | 100.119.512 |
| EC Number | 3.3.2.39 |
| Gmelin Reference | 1205535 |
| KEGG | D04077 |
| MeSH | D000077207 |
| PubChem CID | 60198 |
| RTECS number | KMJ3Z1E472 |
| UNII | P6725D6SCO |
| UN number | UN3341 |
| Properties | |
| Chemical formula | C20H24O2 |
| Molar mass | 296.404 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.8 |
| Acidity (pKa) | 20.06 |
| Basicity (pKb) | 4.33 |
| Magnetic susceptibility (χ) | -8.2e-6 cm³/mol |
| Refractive index (nD) | 1.168 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.12 D |
| Chemical formula | C20H24O2 |
| Molar mass | 296.403 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Insoluble |
| log P | 2.8 |
| Vapor pressure | 0.0000207 mmHg at 25°C |
| Acidity (pKa) | 20.8 |
| Basicity (pKb) | 3.12 |
| Magnetic susceptibility (χ) | -7.6e-6 cm³/mol |
| Refractive index (nD) | 1.126 |
| Dipole moment | 3.2111 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 377.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -123.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8157 kJ/mol |
| Std molar entropy (S⦵298) | 344.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -186.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8112 kJ/mol |
| Pharmacology | |
| ATC code | L02BG06 |
| ATC code | L02BG06 |
| Hazards | |
| Main hazards | May cause harm to unborn children; may cause allergic skin reaction; harmful if swallowed; harmful if inhaled. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 1*3*0 |
| Flash point | 79.5°C |
| Autoignition temperature | 425°C |
| Lethal dose or concentration | LD₅₀ (oral, rat): >4000 mg/kg |
| LD50 (median dose) | LD50 (median dose) for Exemestane: 795 mg/kg (Rat, oral) |
| NIOSH | GXG23810B8 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 25 mg once daily |
| Main hazards | May cause harm to unborn children; harmful if swallowed; may cause irritation to eyes, skin, or respiratory system. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | `GHS07, GHS08` |
| Signal word | Warning |
| Hazard statements | H361 Suspected of damaging fertility or the unborn child. |
| Precautionary statements | P201, P202, P281, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 1-2-0-0 |
| Flash point | 128.1±25.5 °C |
| Autoignition temperature | 595 °C |
| Explosive limits | Lower: 1.1% ; Upper: 6.0% |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral >4580 mg/kg |
| NIOSH | WZB052 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 25 mg once daily |
| Related compounds | |
| Related compounds |
Androstenedione
Formestane Letrozole Anastrozole Testolactone |
| Related compounds |
Androstenedione
Formestane Letrozole Anastrozole |
Providing high-quality chemical products and logistics solutions for global trade partners.
